Drug General Information
Drug ID	D00JFE
Former ID	DIB013280
Drug Name	ARN-810
Indication	Breast cancer [ICD9: 174, 175; ICD10:C50]		Phase 2	[524250]
Company	Seragon pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Estrogen receptor	Target Info	Modulator	[533211]
KEGG Pathway	Estrogen signaling pathway
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Endocrine and other factor-regulated calcium reabsorption
	Proteoglycans in cancer
NetPath Pathway	FSH Signaling Pathway
	EGFR1 Signaling Pathway
	RANKL Signaling Pathway
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Signaling events mediated by HDAC Class II
	Plasma membrane estrogen receptor signaling
	LKB1 signaling events
	Regulation of Telomerase
	ATF-2 transcription factor network
	AP-1 transcription factor network
	FOXM1 transcription factor network
	Validated nuclear estrogen receptor alpha network
	Signaling mediated by p38-alpha and p38-beta
	FOXA1 transcription factor network
Reactome	Nuclear signaling by ERBB4
	Nuclear Receptor transcription pathway
WikiPathways	Estrogen signaling pathway
	Nuclear Receptors Meta-Pathway
	Estrogen Receptor Pathway
	Signaling by ERBB4
	JAK/STAT
	Integrated Pancreatic Cancer Pathway
	Leptin signaling pathway
	miR-targeted genes in muscle cell - TarBase
	Integrated Breast Cancer Pathway
	Nuclear Receptors
References
Ref 524250	ClinicalTrials.gov (NCT01823835) A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer. U.S. National Institutes of Health.
Ref 533211	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem.2015 Jun 25;58(12):4888-904.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.